Measles serologic status in 122 nonvaccinated patients after BMT
| . | Serologic status3-150(%) . | Total . | P . | |
|---|---|---|---|---|
| Susceptible . | Immune . | |||
| Time after BMT, y | ||||
| ≤ 1 | 04 (8.5) | 43 (91.5) | 47 (100) | |
| 1-2 | 11 (36.6) | 19 (63.3) | 30 (100) | |
| ≥ 2 | 26 (57.7) | 19 (42.3) | 45 (100) | |
| Total | 41 | 81 | 122 | <.0001 |
| Type of BMT | ||||
| Allogeneic | 37 (37.4) | 62 (62.6) | 99 (100) | |
| Autologous or syngeneic | 06 (26.1) | 17 (73.9) | 23 (100) | |
| Total | 43 | 79 | 122 | NS |
| Acute GVHD3-151 | ||||
| Grade 1 or absent | 0 (0) | 5 (100) | 5 (100) | |
| Grade ≥ 2 | 2 (20) | 8 (80) | 10 (100) | |
| Total | 2 | 13 | 15 | NS |
| Chronic GVHD3-152 | ||||
| Absent | 27 (48.2) | 29 (51.8) | 56 (100) | |
| Present | 10 (35.7) | 18 (64.3) | 28 (100) | |
| Total | 37 | 47 | 84 | NS |
| Immunosuppressive drugs | ||||
| With | 10 (29.4) | 24 (70.6) | 34 (100) | |
| Without | 27 (41.5) | 38 (58.5) | 65 (100) | |
| Total | 37 | 62 | 99 | NS |
| . | Serologic status3-150(%) . | Total . | P . | |
|---|---|---|---|---|
| Susceptible . | Immune . | |||
| Time after BMT, y | ||||
| ≤ 1 | 04 (8.5) | 43 (91.5) | 47 (100) | |
| 1-2 | 11 (36.6) | 19 (63.3) | 30 (100) | |
| ≥ 2 | 26 (57.7) | 19 (42.3) | 45 (100) | |
| Total | 41 | 81 | 122 | <.0001 |
| Type of BMT | ||||
| Allogeneic | 37 (37.4) | 62 (62.6) | 99 (100) | |
| Autologous or syngeneic | 06 (26.1) | 17 (73.9) | 23 (100) | |
| Total | 43 | 79 | 122 | NS |
| Acute GVHD3-151 | ||||
| Grade 1 or absent | 0 (0) | 5 (100) | 5 (100) | |
| Grade ≥ 2 | 2 (20) | 8 (80) | 10 (100) | |
| Total | 2 | 13 | 15 | NS |
| Chronic GVHD3-152 | ||||
| Absent | 27 (48.2) | 29 (51.8) | 56 (100) | |
| Present | 10 (35.7) | 18 (64.3) | 28 (100) | |
| Total | 37 | 47 | 84 | NS |
| Immunosuppressive drugs | ||||
| With | 10 (29.4) | 24 (70.6) | 34 (100) | |
| Without | 27 (41.5) | 38 (58.5) | 65 (100) | |
| Total | 37 | 62 | 99 | NS |